Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks

The phase 3 ATLAS and FLAIR studies demonstrated that maintenance with Long-Acting (LA) intramuscular cabotegravir and rilpivirine is non-inferior in efficacy to current antiretroviral (CAR) oral therapy. Both studies utilized Patient-Reported Outcome instruments to measure treatment satisfaction (H...

Descripción completa

Detalles Bibliográficos
Autores principales: Murray, Miranda, Antela, Antonio, Mills, Anthony, Huang, Jenny, Jäger, Hans, Bernal, Enrique, Lombaard, Johan, Katner, Harold, Walmsley, Sharon, Khuong-Josses, Marie-Aude, Hudson, Krischan, Dorey, David, Griffith, Sandy, Spreen, William, Vanveggel, Simon, Shaefer, Mark, Margolis, David, Chounta, Vasiliki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667137/
https://www.ncbi.nlm.nih.gov/pubmed/32447500
http://dx.doi.org/10.1007/s10461-020-02929-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667137/
https://www.ncbi.nlm.nih.gov/pubmed/32447500
http://dx.doi.org/10.1007/s10461-020-02929-8

Ejemplares similares